TGTX - TG Therapeutics, Inc.
| Previous Close | 4.4200 |
| Open | 4.4200 |
| Bid | 4.30 x 3200 |
| Ask | 4.52 x 1100 |
| Day's Range | 4.4000 - 4.6000 |
| 52 Week Range | 3.3200 - 17.3500 |
| Volume | 1,320,934 |
| Avg. Volume | 1,207,707 |
| Market Cap | 347.259M |
| Beta (3Y Monthly) | 1.77 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.08 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.50 |
- Zacks•4 days ago
Canopy Growth (CGC) in Focus: Stock Moves 11.1% Higher
Canopy Growth (CGC) shares rose more than 11% in the last trading session, amid huge volumes.
- Thomson Reuters StreetEvents•7 days ago
Edited Transcript of TGTX earnings conference call or presentation 7-Aug-18 8:30pm GMT
Q2 2018 TG Therapeutics Inc Earnings Call
- GlobeNewswire•12 days ago
TG Therapeutics, Inc. to Present at the 37th Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 07, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will.
- GlobeNewswire•12 days ago
Market Trends Toward New Normal in Brunswick, Atkore International Group, TG Therapeutics, Las Vegas Sands, Benchmark Electronics, and ProPetro Holding — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Jan. 07, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Investopedia•19 days ago
The Most Promising Biotech Names Heading Into 2019
Historically, biotech companies have offered investors the possibility of outsized success, but they also carry high levels of risk. The reason for this is that biotech companies traditionally race to develop cutting edge products. When a product in a biotech company's pipeline fails to materialize or to produce the desired results, that company's stock price can suffer the consequences.
- GlobeNewswire•19 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX
Pomerantz LLP is investigating claims on behalf of investors of TG Therapeutics, Inc. (“TG” or the “Company”) (TGTX) Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether TG and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
- ACCESSWIRE•22 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX
NEW YORK, NY / ACCESSWIRE / December 27, 2018 / Pomerantz LLP is investigating claims on behalf of investors of TG Therapeutics, Inc. (''TG'' or the ''Company'') (TGTX) Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. In a press release, TG announced that the trial's Data Safety Monitoring Board had met to review ongoing data from the UNITY-CLL study and advised the Company that the interim analysis of the ORR could not be conducted at that time because the data was not sufficiently mature to conduct the analysis.
- GlobeNewswire•28 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX
Pomerantz LLP is investigating claims on behalf of investors of TG Therapeutics, Inc. (“TG” or the “Company”) (TGTX). Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether TG and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
- ACCESSWIRE•last month
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX
NEW YORK, NY / ACCESSWIRE / December 19, 2018 / Pomerantz LLP is investigating claims on behalf of investors of TG Therapeutics, Inc. (''TG'' or the ''Company'') (TGTX) Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. In a press release, TG announced that the trial's Data Safety Monitoring Board had met to review ongoing data from the UNITY-CLL study and advised the Company that the interim analysis of the ORR could not be conducted at that time because the data was not sufficiently mature to conduct the analysis.
- Zacks•last month
5 Beaten-Down Medical Product Stocks to Rebound in 2019
As the Medical product industry is witnessing temporary sluggishness, a sneak peek into some possible outperformers in 2019 could be a great idea for investors.
- Insider Monkey•last month
Hedge Funds Are Buying TG Therapeutics Inc (TGTX)
“Value has performed relatively poorly since the 2017 shift, but we believe challenges to the S&P 500’s dominance are mounting and resulting active opportunities away from the index are growing. At some point, this fault line will break, likely on the back of rising rates, and all investors will be reminded that the best time […]
- GlobeNewswire•last month
TG Therapeutics, Inc. and Dana-Farber Cancer Institute Announce Publication of Clinical Data from the Phase 1/1b Trial of Umbralisib in Combination with Ibrutinib in Lancet Haematology
TG Therapeutics, Inc. (TGTX) and Dana-Farber Cancer Institute today announced the publication of results from the multicenter Phase 1/1b trial of umbralisib (TGR-1202), TG Therapeutics’ novel once-daily PI3K delta inhibitor, in combination with ibrutinib, the oral Bruton's tyrosine kinase (BTK) inhibitor, in Lancet Haematology. This investigator-initiated trial was conducted at Dana-Farber Cancer Institute and four additional academic and community sites across the USA in collaboration with the Leukemia and Lymphoma Society Blood Cancer Research Partnership with funding by TG Therapeutics.
- GlobeNewswire•last month
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX
Pomerantz LLP is investigating claims on behalf of investors of TG Therapeutics, Inc. (“TG” or the “Company”) (TGTX) Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether TG and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
- ACCESSWIRE•last month
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX
NEW YORK, NY / ACCESSWIRE / December 12, 2018 / Pomerantz LLP is investigating claims on behalf of investors of TG Therapeutics, Inc. (''TG'' or the ''Company'') (TGTX) Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. On September 25, 2018, TG announced that it would not be releasing data from the UNITY-CLL Phase 3 study of the Company's leukemia treatment TG-1101 (ublituximab) and that the study had failed to meet the overall response rate (''ORR'') stated goal.In a press release, TG announced that the trial's Data Safety Monitoring Board had met to review ongoing data from the UNITY-CLL study and advised the Company that the interim analysis of the ORR could not be conducted at that time because the data was not sufficiently mature to conduct the analysis.
- Motley Fool•last month
3 Beaten-Down Biotech Stocks That Could Bounce Back in 2019
A new year and reasons to remain hopeful for these three biotechs are around the corner.
- GlobeNewswire•last month
Recent Analysis Shows Verizon Communications, MGM Resorts International, Exelon, Axon Enterprise, M.D.C., and TG Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Dec. 12, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•last month
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX
Pomerantz LLP is investigating claims on behalf of investors of TG Therapeutics, Inc. (“TG” or the “Company”) (TGTX) Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether TG and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On September 25, 2018, TG announced that it would not be releasing data from the UNITY-CLL Phase 3 study of the Company’s leukemia treatment TG-1101 (ublituximab) and that the study had failed to meet the overall response rate (“ORR”) stated goal. In a press release, TG announced that the trial’s Data Safety Monitoring Board had met to review ongoing data from the UNITY-CLL study and advised the Company that the interim analysis of the ORR could not be conducted at that time because the data was not sufficiently mature to conduct the analysis.
- GlobeNewswire•last month
Deadline Alert: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Trevena, Inc.
Law Offices of Howard G. Smith reminds investors of the December 10, 2018 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Trevena, Inc. (“Trevena” or the “Company”) (NASDAQ: TGTX) securities between May 2, 2018 and October 8, 2018, inclusive (the “Class Period”). Trevena investors have until December 10, 2018 to file a lead plaintiff motion. Investors suffering losses on their Trevena investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
- Simply Wall St.•last month
Is TG Therapeutics Inc’s (NASDAQ:TGTX) CEO Overpaid Relative To Its Peers?
In 2011 Mike Weiss was appointed CEO of TG Therapeutics Inc (NASDAQ:TGTX). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...
- Thomson Reuters StreetEvents•last month
Edited Transcript of TGTX earnings conference call or presentation 9-Nov-18 1:30pm GMT
Q3 2018 TG Therapeutics Inc Earnings Call
- GlobeNewswire•2 months ago
TG Therapeutics, Inc. Announces Follow-Up Data from the Triple Combination of Ublituximab, Umbralisib, and Bendamustine in Patients with DLBCL and FL at 60th American Society of Hematology Annual Meeting and Exposition
TG Therapeutics, Inc. (TGTX), today announced updated clinical data from its Phase I/Ib trial of ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody in combination with umbralisib (TGR-1202), the Company’s oral, next generation PI3K delta inhibitor, and bendamustine, in patients with Diffuse Large B-cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer stated, “The data presented yesterday further supports our belief that our proprietary U2 combination is an ideal backbone regimen on which to build novel multi-drug combinations.
- GlobeNewswire•2 months ago
CLASS ACTION DEADLINE for TGTX, ACHC and ADNT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, Dec. 03, 2018 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
- GlobeNewswire•2 months ago
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against TG Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against TG Therapeutics, Inc. (“TG Therapeutics” or “the Company”) (NASDAQ: TGTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. TG Therapeutics was engaged in cleaning the data collected from its UNITY-CLL study, which gave it an understanding of the efficacy of the combination therapy.
- GlobeNewswire•2 months ago
FINAL DEADLINE ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against TG Therapeutics, Inc. (TGTX) & Lead Plaintiff Deadline - December 3, 2018
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (TGTX) on behalf of shareholders who purchased or otherwise acquired TG Therapeutics securities between June 4, 2018 and September 25, 2018, (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/tgtx. This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information about the Company.
